How Great Biotech CEOs Solve the Complex Problems Behind Their Innovation

CEOs in any industry face certain challenges around innovating. In biotechnology, these problems can lead to projects being stalled, original plans being scrapped, and even nothing to show for it in the end. But CEOs who are on the forefront of biotech innovation, know that they need to understand the different roadblocks that come up and have solutions to help them overcome them. They solve these problems by knowing the connections between the business and science, how to get funding when no product could be ready for years, and more. Let’s take a closer look at how they are pushing through some of the top problems behind their innovative ideas.

When the Science Meets Business

Biotechnology is an ever-evolving industry with new breakthroughs and discoveries happening all the time. Biotech CEOs have to strike the balance between innovation in science and keeping the business afloat and moving forward. Whether it’s in the field of robotics or in molecular biology, these business leaders understand how to keep things moving along.

If the projects they are trying to complete require specific starting materials, like DNA, for example, they know how important it is to invest in the right thing. They don’t want inaccurate DNA when what they need most is a specific gene sequence to work with. They look at what happens in DNA synthesis to ensure that they choose an option that gives them accurate results. Many older processes used template-based processes. The leading research now allows for enzymatic DNA synthesis to get controlled results. The outcome of the new ways of doing things gives them sustainable and accurate DNA chains they can use in research and creating new biological products.

When the Research Outcomes are Uncertain

When you’re innovating within the biotech world, it’s imperative that you are able to research effectively. Unfortunately, many cuts to scientific funding has left biotech companies scrambling and looking for ways to validate their work when the outcomes of the research are unknown. While timelines today are much quicker than they were 30 years ago, thanks to advances in science and technology, it’s still important to fund research that has unknown outcomes.

Exploring how something works or what environmental factors influence biology may sound useless to some, but it’s these questions that help scientists create better medicines and treatments that help people live longer and healthier. CEOs have to navigate this landscape so that they can innovate effectively. One of the ways they are handling these challenges is to get a Chief Science Officer on board who knows the ins and outs of the research and what they hope to accomplish with what they are doing.

Getting Financing Before a Product is Ready

Creating a new biotechnology product isn’t as simple as making a new refrigerator. The timelines from ideation to market are extremely long in comparison to most other industries. Getting capital becomes a much different conversation especially when a high percentage of medications aren’t able to ever get FDA approval after human trials. Securing the money that biotech CEOs need in order to run their businesses becomes a big challenge.

They often seek investors who are okay with a long time until they get a good ROI. They often need to meet certain milestones and deliverables even if the final product isn’t ready to sell. This can be anything from starting simulations with a prototype to getting to the point of human trials. While getting the money to work on the project can be difficult, biotech CEOs learn how to find the right investors who want to be a part of cutting-edge innovation.

NDAs and Intellectual Property

When you’re working in a sensitive environment like biotechnology, holding onto intellectual property rights and keeping things a secret is imperative. CEOs know how important it is for all employees to keep the details of their work private. It protects the science behind the work they are doing and ensures that there are no leaks to other companies who might want to try and steal their work. All employees working in the biotech industry know that NDAs are part of the job.

Figuring Out Regulations When the Tech is Changing

How do you regulate something that doesn’t exist yet? This is the challenge that many CEOs in the biotech industry are facing. They are innovating so fast that the ways to regulate their products and processes don’t even exist yet. While some might look at this as a good thing, because they can innovate outside the lines, CEOs also know that certain regulations can protect themselves and the people who will use their products.